Advertisement
Canada markets close in 4 hours 56 minutes

  • S&P/TSX

    21,746.30
    -127.42 (-0.58%)
     

  • S&P 500

    5,005.92
    -65.71 (-1.30%)
     

  • DOW

    37,811.48
    -649.44 (-1.69%)
     

  • CAD/USD

    0.7295
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    82.11
    -0.70 (-0.85%)
     

  • Bitcoin CAD

    86,928.13
    -2,279.51 (-2.56%)
     

  • CMC Crypto 200

    1,372.84
    -9.74 (-0.70%)
     

  • GOLD FUTURES

    2,345.70
    +7.30 (+0.31%)
     

  • RUSSELL 2000

    1,966.23
    -29.20 (-1.46%)
     

  • 10-Yr Bond

    4.7140
    +0.0620 (+1.33%)
     

  • NASDAQ

    15,455.75
    -257.00 (-1.64%)
     

  • VOLATILITY

    17.07
    +1.10 (+6.89%)
     

  • FTSE

    8,059.63
    +19.25 (+0.24%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

MediWound to Report First Quarter 2023 Financial Results

MediWound Ltd.
·2 min read
MediWound Ltd.
MediWound Ltd.

Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time

YAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 on Tuesday, May 30, 2023.

Following the release, MediWound's management will host a conference call and live webcast at 8:30am Eastern Time to discuss the financial results, provide corporate updates and answer questions.
Dial-in and call details are as follows:

Conference Call & Webcast Details

 

Toll-Free:

1-833-630-1956

Israel:

1-80-921-2373

International:

1-412-317-1837

Webcast:

Click HERE

 

 

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.  An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

ADVERTISEMENT

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx®. EscharEx is a Phase III biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. The Phase III study is expected to start in Q4 2023. Additionally, MediWound has a Phase I/II biologic for basal cell carcinoma, MW005, with results expected in Q3 2023.

For more information visit www.mediwound.com and follow the Company on LinkedIn.

Contacts:

 

 

 

 

Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
ir@mediwound.com

 

 

 

Monique Kosse
Managing Director, LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com